The cytokines IL-10 and TNF-a cause cachexia and hypermetabolism in animal models, but their role in human inflammation remains controversial. The relationship between in vitro cytokine production and metabolism was examined in 23 adults with RA and 23 healthy control subjects matched on age, sex, race, and weight. Body composition was measured by multicompartmental analysis of body cell mass, water, fat, and bone mass. Resting energy expenditure (REE) was measured by indirect calorimetry. Cytokine production by PBMC was measured by radioimmunoassay. Usual en4gy intake, physical activity, disability scores, medication use, and other confounders were also measured.
Introduction
Cachexia, from the Greek "bad condition," generally connotes a state of advanced malnutrition and wasting. However, more recently cachexia has been used to denote the loss of body cell t Deceased. mass (BCM)' which occurs in illness (1) . BCM accounts for over 95% of body metabolic activity (2) . The most important aspect ofthis categorization is that loss ofBCM is a very powerful predictor of outcome in starvation, critical illness, and normal aging (3) . Loss of BCM is a hallmark of aging, and a decline in BCM, and especially muscle mass, is seen in both men and women after age 60 (4) . In all clinical situations in which it has been studied (5) (6) (7) , loss of> 40% ofbaseline BCM is associated with death. This has led us (8) and others ( 1, 9) to suggest that loss ofBCM is an important marker ofphysiologic health and a potential nonchronologic marker of aging.
Loss of BCM presumably requires a net catabolic process, with negative energy, protein, and micronutrient balances over some period oftime. These losses may occur over days to weeks in critical illness, over months to years in chronic illness, and over decades in physiologic aging. Losses that occur over prolonged periods of time are not measurable with standard balance techniques and often can only be detected indirectly by measurement ofbody composition changes. In trying to understand the mechanisms behind cachexia, the mediators ofcatabolism in infectious, neoplastic, and inflammatory conditions have been studied extensively. For example, serum from septic humans can cause catabolism when incubated with muscle from healthy rats (10, 11 ) . Since septic sera contain TNF-a and IL-I#, it has been suggested that these are the inflammatory mediators that lead to loss of BCM in cancer and infectious diseases such as AIDS( 1, 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, other studies have failed to show a direct catabolic effect of these cytokines in animals, and the existence ofother mediators has been postulated (14) (15) (16) . We examined these questions in a chronic inflammatory condition, RA. We chose to study RA for several reasons. First, high levels of TNF-a and IL-13 have been demonstrated in synovial fluid and in circulation ofpatients with RA ( 17, 18) . Also, mortality in RA exceeds that in the general population by two-to fivefold (19) (20) (21) . In addition, RA does not typically cause malabsorption or hepatic or renal disease (22) , greatly simplifying the study of the impact of chronic inflammation on nutritional and metabolic parameters. Furthermore, we have shown previously that adults with RA have reduced BCM, a form of the "rheumatoid cachexia" first described by Sir James Paget (23) (24) (25) . However, while Paget and most rheumatologists since have considered rheumatoid cachexia to be very unusual on the basis of clinical observation alone, evidence for loss of BCM was found in two-thirds of our subjects. In addition, serum TNF-a levels were elevated during disease flare only in those subjects who had lost BCM, but not in apparently equally affected patients with normal BCM, suggesting that cytokine production could be driving the loss of BCM seen in RA (24) . The current study was designed both to quantify the extent of loss of BCM and to investigate possible causes of this loss.
Methods
Study design. A cross-sectional study was conducted on 23 subjects with RA and 23 matched controls. Each subject was studied once.
Study population. Subjects with RA were recruited from the rheumatology clinics at New England Medical Center and affiliated rheumatology practices. All subjects met the American College of Rheumatology (ACR) criteria for RA (26) . Cases were matched to healthy controls on the basis of age (within 5 yr), sex, race, and weight (within 5 kg). RA disease severity was assigned before knowledge of outcomes was available, based on the ACR criteria for functional status in RA (27) . Subjects who met ACR functional class 1 criteria were considered as mild, class 2 as moderate, and class 3 or 4 as severe RA. In contrast to severity, disease activity was carefully controlled: all subjects with RA had to be considered by their rheumatologist to be under good disease control, without change in medication dosage over the previous 3 mo. Potential subjects were excluded if they had diarrhea, proteinuria, serum creatinine over 1.3 mg/dl, or abnormal liver transaminases; otherwise subjects were recruited sequentially without selection by weight, body habitus, or disease duration. 15 of the RA subjects were not taking prednisone at the time of study; 9 of these participants had never taken prednisone. 10 of the RA subjects were not taking nonsteroidal antiinflammatory medications (NSAID).
Body composition. Body composition was determined by measuring four bodily compartments independently. BCM was determined by potassium-40 whole body counting, which relies on the ability to measure total body potassium (TBK), the main intracellular cation, by detecting the amount of naturally radioactive potassium-40 present in the body. The coefficient of variation (c.v.) for TBK at our institution is < 3% (8) . Total body water (TBW) was measured by tritium dilution (c.v. 2% [28] ). Bone mineral mass was measured by dual-energy x-ray absorptiometry (model DPX; Lunar Radiation Corp., Madison, WI) (c.v. 0.6% [29] ), and fat was measured by the same method (c.v. 1.7% [29] ). This approach does not make assumptions about the hydration of lean body mass (LBM) that may be erroneous in RA or in the elderly; calculations ofLBM or fat mass (FM) based on TBW were not done to avoid such potential errors. Furthermore, by measuring each compartment independently, the measurement error ofone compartment is not propagated to another compartment (8) . Compartments were not summated because there is overlap between TBW and BCM. Comparisons between cases and controls were performed using unadjusted data and also after adjusting for stature using knee height, which is not influenced by osteoporotic loss of vertebral height which may be biased between cases and controls (30) .
Cytokine production. PBMC were obtained from whole blood by Ficoll-Hypaque centrifugation as described previously and washed three times in sterile, pyrogen-free saline (31, 32) . Cells were suspended at 5 x 106/ml in RPMI (Sigma Chemical Co., St. Louis, MO) which had been subjected to ultrafiltration (33) to remove cytokine-inducing substances. Ultrafiltered RPMI was supplemented with indomethacin (50 ,g/ml), 100 gg/ml streptomycin, and 100 U/ml penicillin (Sigma Chemical Co.) and contained 2% autologous heat-inactivated serum. Cells were cultured in 24-well flat-bottomed plates; each well contained 0.5 ml of cells plus 0.5 ml of RPMI or Escherichia coli endotoxin (B55:0; Sigma Chemical Co.) at 1, 10, or 100 ng/ml. After 22 h at 37-C in 5% C02, the plates were frozen at -800C. Plates Energy expenditure. Resting energy expenditure (REE) was measured by indirect calorimetry. Oxygen consumption and carbon dioxide production were measured over 20 min under thermoneutral conditions in the morning after an overnight fast of 10-12 h. The measurements were made after subjects rested supine for 30 min. The subjects were instructed to relax and avoid hyperventilation, fidgeting, and sleeping during measurements. The measurements were made while the subjects breathed through a low-resistance mouthpiece. Expired air was collected in a calibrated Tissot spirometer and an open-circuit respiratory collection system (Warren E. Collins, Inc., Braintree, MA). Oxygen consumption was measured using an oxygen sensor and an oxygen analyzer(N-22M and S-3A, respectively; Applied Electrochemistry, Sunnyvale, CA). CO2 production was measured using a medical gas analyzer (LB-2; Beckman Instruments, Inc. Anaheim, CA). Values for REE were calculated using Weir's equation (36) .
Physical activity was estimated using the Paffenbarger questionnaire (37) . Subjects were asked to estimate the number of hours they usually spent in various activities, separately for weekdays and weekends. Activities were grouped by strenuousness into light, moderate, and heavy; specific examples ofeach were given; and the questionnaire was reviewed with the subject for clarity and understanding. The number ofhours per day that subjects reported they spent in each activity is presented. Self-reported hours of sleep were also determined by questionnaire for weekdays and weekends.
Other measurements. Usual dietary intake was measured by a food frequency questionnaire (Health Habits and History Questionnaire [38] ), validated previously by seven nonconsecutive 24-h diet histories in patients with RA (Roubenoff, R., L. W. Grimme, and R. A. Roubenoff, unpublished observations). The correlation between the food frequency instrument and the validation was 0.80 for energy and 0.68 for protein intake, which is typical of the correlations seen with such instruments (39) . Disability was measured using the disability and pain scales of the Health Assessment Questionnaire (40 
Results

Study population
In total, 46 subjects were studied, 23 (27) . Disease activity at the time of study was low in all subjects, who were taking stable doses of medication and had sedimentation rates and durations of morning stiffness that suggest good disease control (Table I and Methods). 15 To examine the potential influence of corticosteroid therapy further, stature-adjusted TBK was examined in four groups: those who had never taken prednisone; those who had taken prednisone previously but were not currently doing so; those who were currently taking prednisone, and the control group. While there was a small difference in BCM between those patients taking prednisone and those who had never taken this medication, this was dwarfed by the magnitude of the difference between controls and subjects with RA (Fig. 1 ) Figure 1 . Mean (±SEM) stature-adjusted BCM for control subjects and subjects with RA by prednisone history (never took prednisone, took prednisone previously but not within the past 6 mo, or currently taking prednisone).
suggesting that some of the decline in BCM associated with prednisone use may in fact be due to disease severity.
Cytokine production
Production ofTNF-a was higher in PBMC's from subjects with RA than from controls. This was observed in unstimulated cells and in cells stimulated with all three concentrations of endotoxin (P < 0.05, Fig. 2) . Similarly, mean IL-1,8 production was higher in cells from patients with RA than controls, but the differences were only statistically significant at and 10 ng/ml of endotoxin (P < 0.01, Fig. 2 ).
REE, dietary energy intake, and physical activity Although absolute REE was not different between subjects with RA and controls (mean REE = 1,413 vs 1,410 kcal/d, P = NS), REE was higher in cases than controls after adjustment for BCM (mean adjusted REE = 1,489 vs 1,332 kcal/d; P < 0.008, analysis of covariance; see Fig. 3 and Table II) . Furthermore, REE increased with RA severity, just as BCM fell (P < 0.0003, ANOVA for trend). Cigarette smoking, which can ng/ml Difference between the two groups is significant (P < 0.008, analysis of covariance).
influence REE, did not differ between cases and controls (P < 0.38). TSH levels were normal in all subjects and did not differ between cases and controls (P < 0.30). There was no difference between RA and control groups in mean energy or protein intake (Table II) . As expected, subjects with RA reported less physical activity than controls by Paffenbarger questionnaire (Table II) , especially for vigorous activity (0. vs 1.5 h, P < 0.0001), and longer sleeping hours than controls (8.0 vs 7.3 h, P < 0.03).
Multivariate analysis
Multivariate linear regression was used to analyze biologically plausible parameters that explained significant amounts ofthe variability in REE and energy intake (Table III) . REE. In the control subjects, only BCM and sex were significant explanatory variables, with higher REE in men. This was consistent with the concept that sex is a surrogate marker for muscle mass, which is an important determinant of REE. In the subjects with RA, in contrast, BCM, IL-I11, and TNF-a production by unstimulated PBMCs and the interaction between IL-I13 and TNF-a (IL-l X TNF) were all significant explanatory variables. The signs of the coefficients were positive, indicating that the higher the basal cytokine production the higher the REE (42, 43) , analysis of multiple compartments in this chronic inflammatory condition has not been attempted before. Elevated production of TNF-a and IL-IB has been described in RA during times of disease activity ( 17, 18) . However, it is generally not possible to find detectable levels of cytokines during times of disease quiescence (23) . Nevertheless, we were able to demonstrate increased cytokine production by PBMC from subjects with RA. By studying cytokine production by PBMC, we avoided many methodologic proW lems associated with measuring circulating cytokines, such as those posed by binding proteins, rheumatoid factor, etc. (44) . In addition, because it is thought that much of the effect of cytokines occurs in a paracrine or autocrine fashion, circulating levels may not be accurate reflections ofthe in vivo activity of cytokines at the tissue level; if levels are undetectable, this does not prove that the cytokine is not in fact acting locally. Measurement of cytokine production by unstimulated and stimulated PBMC appears to us to be the best compromise between precision and validity. It would also be ofgreat interest to examine cytokine production by synovial cells rather than PBMC; this was not done in the present study to minimize invasiveness, as joint effusions were uncommon in this patient group with clinically controlled disease.
In addition, after adjustment for BCM, REE was significantly higher in our subjects with chronic inflammation, even when their condition was clinically well controlled. In multivariate analysis, we found that higher IL-13 and TNF-a production was associated with increased REE in the RA group, suggesting that excessive production of inflammatory cytokines is linked to hypermetabolism. The finding of hypermetabolism and loss of BCM associated with cytokine production has been demonstrated in animals ( 13, (45) (46) (47) and in cytokine infusion studies in humans ( 12, 48) . However, this study demonstrates for the first time an association between REE and in vitro cytokine production by PBMC, without intravenous administration of cytokine. The presence of this association even in a group with low disease activity suggests that the hypermetabolism of chronic inflammation smolders even when good clinical control of RA is achieved.
The inverse association between IL-1B production and energy intake in subjects with RA may also be important. The role of inflammation in suppressing appetite has been demonstrated in animals (46, 49), but has not been demonstrated clearly in humans. We found no overall difference in energy intake between patients and controls (Table II) ; however, the inverse association between IL-1,3 production and dietary intake suggests that cytokine production may lead to a relative, rather than absolute, anorexia. In the RA group, IL-Iinduced relative anorexia may aggravate the loss of BCM that occurs in the hypermetabolic state by preventing patients from increasing their intake to meet their higher energy needs. These data also suggest that IL-1I3 and TNF-a have different but reinforcing metabolic effects in chronic inflammation. Some caution should be exercised in interpreting these data, as self-reported intakes are subject to many errors (39) . However, there is no indication that these errors introduce a bias in dietary assessment between cases and controls (see Methods).
In addition to cytokine-associated elevated REE and relative reduction in intake, a third important determinant of rheumatoid cachexia may be reduced physical activity. As expected, our subjects with RA demonstrated markedly lower levels ofvigorous physical activity compared with controls and moderately lower levels ofmoderate and light activity. Subjects with RA also slept longer hours than controls, although the sleep disturbances that occur in RA (50) may also lead to higher REE during sleep in RA. It should be noted that because we relied on self reports of physical activity and sleep, these results could be biased if patients systematically over or under report their activities compared with controls. However, it is more likely that a patient with RA would consider as "vigorous" what a healthy person would consider "moderate" than the reverse, resulting in a bias against finding an association rather than in its favor. With respect to dietary intake, we have previously validated our instrument in adults with RA and found no bias in reporting intake compared with healthy subjects (51). We hypothesize that the combination of dietary, physical activity, and metabolic abnormalities acts to increase catabolic stimuli while reducing anabolic ones and leads to the loss of BCM seen in rheumatoid cachexia.
We found no direct association between low BCM and increased cytokine production, although both conditions occurred in the RA group. This is not surprising for several reasons. First, changes in BCM occur over months to years, while cytokine production changes from day to day, although between-subject variability is greater than intra-subject day-today variation (31 ) . In contrast, changes in REE occur on the same time scale as changes in BCM. For this reason, our a priori hypothesis was to relate cytokine production to REE rather than BCM. We hypothesize that the hypermetabolism in the face of no increase in intake in turn leads to erosion of BCM. Second, we have shown previously (24) that hypercytokinemia is greatest during disease flare. Thus, we expect that hypermetabolism, relative anorexia, and erosion ofBCM accelerate during times of heightened disease activity. This study was designed to include people with well controlled disease and could not test this hypothesis. Third, many (46, 47, 49) but not all ( 14) animal studies offer biologic plausibility to the association between cytokine production and cachexia, but these longitudinal infusion studies are difficult or impossible to perform in humans. In one human study ( 12) , TNF administration led to doubling offorearm amino acid efflux, a metabolic derangement that would predispose to cachexia. Finally, from a statistical point of view, this study did not have adequate power to reject a null hypothesis ofno association between differences in cytokine production within case-control pairs and differences in BCM, because ofthe nonnormal distribution of residuals of differences in cytokine production. Thus, we conceptualize change in BCM as the "area under the curve" of a person's metabolic state: as such, it is the summation of their cytokine status over many years at different levels ofdisease activity that we would expect to correlate with BCM and not their cross-sectional production on the day of study.
There are several other limitations of this study. First, the small sample size, dictated by the technologically intensive nature ofthe work, suggests that replication in other populations is needed. For example, larger-scale studies of body composition in RA could be undertaken using bioelectrical impedance, based on population-specific equations derived from the data presented here. Second, the contribution of other mediators of body composition and energy expenditure, such as growth hormone, androgens, and cortisol, was not studied, although thyroid status was within normal limits in all subjects.
Third, the potential effect ofcorticosteroids and other medications in these results should not be ignored. Our results apply to patients with RA who are treated in the conventional manner. Eight of our subjects with RA were taking prednisone at the time ofthe study, with a mean dose of9.9 mg/d (Table I) . Since cytokine production is reduced by prednisone, it is unlikely that the results seen here are due to corticosteroid effects (52) . Although glucocorticoids play a role in the loss of body calcium seen in RA (42, 43) , their effect on BCM is less clear. Body composition was abnormal in RA patients regardless of steroid status (Fig. 1) , and prednisone was not a significant explanatory variable for REE (Table III) . However, prednisone dose is a strong marker ofdisease severity (Fig. 1) , and we cannot evoke a scenario in which people with RA can be studied completely free of steroid or other drug effects. Svenson et al. (53, 54) have shown that metabolic parameters in RA are abnormal during inflammation and are normalized by the use of low-dose corticosteroids. While we have shown that highdose "pulse" corticosteroids cause obligate loss of nitrogen in people with RA (23), low-dose oral glucocorticoids may be protective of LBM by reducing inflammation and improving functional status to a greater extent than they cause catabolism (24) . Further, it is unlikely that either methotrexate or azathioprine would affect energy metabolism in RA, as recent data suggest that even much higher doses of these medications do not alter REE in humans (55) .
Furthermore, although very high doses of aspirin (5,500 mg/d) can increase REE, this effect has not been seen with other NSAID at antiinflammatory doses (56) . In our population, no effect of NSAID on REE was seen in multivariate linear regression (Table III) . Moreover, the effect ofNSAID on in vitro cytokine production was abrogated since indomethacin was added to cultures ofcells ofpatients and controls. This has been shown to reduce the effects of oral NSAID without affecting the rank order of subjects with respect to cytokine production (31 ) . The mechanism by which NSAID increased dietary intake in our subjects with RA remains speculative: perhaps reduction of prostaglandin production improved appetite, or it may be that patients with RA were following instructions to take their NSAID with food to reduce the risk of NSAID gastropathy.
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